Kansas City funeral home searches for family after body left at morgue for months
Iowa woman says man she was dating confessed he was on the run, wanted for murder in Texas
Black motorist fatally shot by London police officer in 2022 was a member of a violent gang
ECB's Knot: falling interest rates should ease debt burdens
South Africa sees Russia as a valued ally, Ramaphosa tells Putin
Norfolk Southern posts upbeat quarterly results on improving rail service, volumes
Russia to use ship-to-ship LNG loadings to free up ice-class tankers
AARP to honor Glenn Close with Movies for Grownups career achievement award
NBA things to know: As season begins, Celtics chasing Spurs for all-time best record
30 spooky Halloween things to do near you
By Svea Herbst-Bayliss
NEW YORK (Reuters) - Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.
Starboard Chief Investment Officer Jeffrey Smith said there is an opportunity to improve revenue growth and margins at the segment which has the Neutrogena and Aveeno brands.
"They need to focus on skin health beauty," Smith said, joking "this sounds simple, right? Now they just have to do it."
The hedge fund has built a sizable stake in the consumer products company that makes Band-Aid, Listerine, and Tylenol. Kenvue went public last year and is worth roughly $44 billion.
Kenvue, previously a part of Johnson & Johnson, has seen its stock price fall 18% since the company was listed publicly in May, 2023. It closed trading at $22.92 per share on Monday.
Smith was speaking at the 13D Monitor Active-Passive Investor Summit.
(Reporting by Svea Herbst-Bayliss; Editing by Kirsten Donovan)
